Entia

The company's main offering is the Entia Liberty platform, a service that includes the world's first at-home full blood count (FBC) analyser for cancer patients. This laptop-sized device allows patients to perform a blood test with a single drop of blood from the comfort of their home. The results, along with patient-reported symptoms and vital signs, are securely shared with healthcare professionals via a digital dashboard. This enables clinicians to monitor patients in real-time, detect complications like neutropenia early, and intervene in a timely manner. The goal is to reduce unplanned hospitalizations, keep treatments on schedule, and potentially improve survival outcomes.

Entia's business model involves partnering with healthcare providers, such as NHS trusts in the UK, and life-science companies to integrate the Liberty platform into clinical practice and patient support programs. The company has received UKCA mark approval for its analyser, allowing for its rollout across the UK, and has plans for international expansion, including the US market. Entia has raised approximately $41.3 million in funding over several rounds, with major investors including BGF and Parkwalk. The technology has been developed and tested through collaborations with major cancer centers and trials involving over 1,000 patients.